Search Results 411-420 of 18359 for alopecia
... Alopecia areata, Scarring alopecia, Tinea versicolor, Rosacea, Melasma, Vitiligo, Vascular malformation, Nonmelanoma skin cancer, Tuberous sclerosis ...
* Participants must have recovered to ≤ Grade 2 from all clinically significant toxicities related to prior therapies except alopecia. Key exclusion ...
... alopecia and Grade 2 peripheral neuropathy. For France only: A subject will be eligible for inclusion in this study only if either affiliated to or a ...
Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia. Rochester, Minn., Mankato, Minn., Albert Lea, Minn ...
*Note: Any adverse events derived from these therapies must be ≤ Grade 2 prior to starting study therapy (exception: alopecia). Participating Mayo Clinic ...
- Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia. - Prior external-beam RT resulting in greater than 20% of total bone ...
... Alopecia areata, Melasma, Vascular anomaly, Dermatitis, Morphea, Skin problems, Vulvar skin disorder, Breast skin change, Rosacea, Pigmentation disorder ...
- All grades of alopecia are acceptable; - Endocrine dysfunction on replacement therapy is acceptable. - Severe or unstable medical condition, including ...
Patients with vitiligo or alopecia; ... Any unresolved toxicity National Cancer Institute (NCI) CTCAE v 5.0 Grade ≥ 2 from previous anticancer therapy, with the ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!